ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0017

Xist Ribonucleoproteins Promote Female Sex-biased Autoimmunity

Diana Dou1, Yanding Zhao1, Julia Belk1, Yang Zhao1, Kerriann Casey2, Derek Chen1, Rui Li1, Bingfei Yu1, Suhas Srinivasan1, Brian Abe1, Katerina Kraft1, Ceke Hellström3, Ronald Sjöberg4, Sarah Chang5, Allan Feng5, Daniel Goldman6, Ami Shah7, Michelle Petri6, Lorinda Chung8, David Fiorentino9, Emma Lundberg10, Anton Wutz11, Paul Utz5 and Howard Chang1, 1Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Department of Dermatology, Stanford University School of Medicine, Stanford, CA, 2Department of Comparative Medicine, Stanford University, Stanford, CA, 3Autoimmunity and Serology Profiling, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, 4Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, 5Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 8Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 9Department of Dermatology, Stanford University School of Medicine, Menlo Park, CA, 10Departments of Bioengineering and Pathology, Stanford University, Stanford, CA, 11Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology, ETH Hönggerberg, Zurich, Switzerland

Meeting: ACR Convergence 2023

Keywords: autoantigens, autoimmune diseases, genomics, Mouse Models, Lupus, Non-coding RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0013–0039.5) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmune diseases disproportionately affect females more than males. The XX sex chromosome complement is strongly associated with susceptibility to autoimmunity. Xist long noncoding RNA (lncRNA) is expressed only in females to randomly inactivate one of the two X chromosomes to achieve gene dosage compensation. The Xist lncRNA complexes with numerous proteins associated with autoimmune diseases as autoantigens. The goal of our study is to determine whether the Xist ribonucleoprotein (RNP) complex is a driver for female-biased autoimmunity.

Methods: We developed a unique transgenic mouse to confer inducible expression of a non-silencing form of Xist in male animals. We assessed disease severity/progression in Xist-expressing/non-expressing mice in the pristane-induced systemic lupus erythematous (SLE) model using ATAC-seq, RNA-seq and single cell multiomic analyses of splenic immune cells, histopathology of physical disease markers in tissue sections, and serum autoantibody levels. We screened ChIRP-MS datasets to develop an XIST protein antigen array to test autoimmune disease patient serum for reactivity to XIST complex proteins.

Results: Inducible transgenic expression of Xist in male mice introduced Xist RNP complexes and sufficed to produce autoantibodies. Male SJL/J mice expressing transgenic Xist developed more severe multiorgan pathology in pristane-induced model of lupus than wild-type males. Xist expression in males reprogrammed T and B cell population and chromatin states to more resemble wild type females. Human autoimmune disease patients displayed significant levels of autoantibodies to multiple components of the XIST RNP.

Conclusion: Xist is a sex-specific lncRNA that scaffolds ubiquitous RNP components to drive sex-biased immunity.

Supporting image 1

Proposed model of XIST ribonucleoproteins (RNPs) in autoimmune progression: Autoreactivity to Xist RNPs first causes changes in the chromatin landscape impacting genomic accessibility and changes in lymphocyte gene expression programs prior the development of autoantibodies. Prolonged self-reactive activity damages organs in the final stages of autoimmunity.


Disclosures: D. Dou: None; Y. Zhao: None; J. Belk: None; Y. Zhao: Synthego, 3; K. Casey: None; D. Chen: None; R. Li: None; B. Yu: None; S. Srinivasan: None; B. Abe: Eli Lilly, 3; K. Kraft: None; C. Hellström: None; R. Sjöberg: None; S. Chang: Genentech, 3; A. Feng: None; D. Goldman: None; A. Shah: Arena Pharmaceuticals, 5, Eicos Sciences, 5, Kadmon Corporation, 5, Medpace LLC, 5; M. Petri: Alexion, 1, Amgen, 1, AnaptysBio, 1, Annexon Bio, 1, Argenx, 1, Arhros-Focus Med/Ed, 6, AstraZeneca, 1, 5, Aurinia, 1, 5, 6, Axdev, 1, Biogen, 1, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CVS Health, 1, Eli Lilly, 1, 5, Emergent Biosolutions, 1, Exagen, 5, Exo Therapeutics, 2, Gilead Biosciences, 2, GlaxoSmithKlein(GSK), 1, 5, 6, Horizon Therapeutics, 2, Idorsia Pharmaceuticals, 2, IQVIA, 1, Janssen, 1, 5, Kira Pharmaceuticals, 2, MedShr, 6, Merck/EMD Serono, 1, Momenta Pharmaceuticals, 2, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Proviant, 2, Sanofi, 2, Sinomab Biosciences, 2, Thermofisher, 5, UCB, 2; L. Chung: Eicos Science, 1, 2, Eli Lilly, 1, 2, Genentech, 1, 2, IgM biosciences, 1, 2, Janssen, 1, 2, Kyverna, 1, 2, Mitsubishi Tanabe, 1, 2; D. Fiorentino: None; E. Lundberg: None; A. Wutz: None; P. Utz: None; H. Chang: 10x Genomics, 1, Accent Therapeutics, 8, Arsenal Biosciences, 1, Boundless Bio, 8, Cartography Biosciences, 8, Chroma Medicine, 1, Orbital Therapeutics, 8, Spring Discovery, 1.

To cite this abstract in AMA style:

Dou D, Zhao Y, Belk J, Zhao Y, Casey K, Chen D, Li R, Yu B, Srinivasan S, Abe B, Kraft K, Hellström C, Sjöberg R, Chang S, Feng A, Goldman D, Shah A, Petri M, Chung L, Fiorentino D, Lundberg E, Wutz A, Utz P, Chang H. Xist Ribonucleoproteins Promote Female Sex-biased Autoimmunity [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/xist-ribonucleoproteins-promote-female-sex-biased-autoimmunity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/xist-ribonucleoproteins-promote-female-sex-biased-autoimmunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology